Cell therapy manufacturing

World-class science focused on saving and improving patients’ lives
Cell therapies continue to advance at a rapid pace, with tremendous innovation and investment fueling novel treatments to cure diseases, improve patients’ lives, and tackle medical conditions previously regarded as difficult or impossible to treat. Center for Breakthrough Medicines (CBM) is a CDMO positioned to support the full cell therapy product lifecycle from early development to large-scale commercial production. Our team has unparalleled prior experience in advancing cell therapies to IND and all the way to commercialization, and our clients can leverage our large single-site facility, capable of fully integrated production, with flexible suites and client-centric program management.
Capabilities to develop autologous and allogeneic therapies

GMP workflows and equipment support a range of cell therapies
World-class processes and production platforms
Cell-Derived Therapies
- CAR-T Cells
- TCR
- Dendritic Cell & NK Cell
- TILs
- Treg
Tissue-Derived Therapies
- iPSC
- Mesenchymal Stem Cells
- Hematopoietic Stem Cells
CBM supports clients with agile, flexible cell capabilities
Rapid development and full program transparency
- qPCR, rapid micro methods, flow cytometry, ELISA, and automated cell counting.
- Incoming raw material, in-process and final product testing.
- Network of qualified contract testing laboratories to supplement in-house capabilities.
- Environmental, personnel and utility monitoring.

Analytical methods development is performed in-house
Drug Substance
- Potency
- Viability
- Safety
- Mycoplasma PCR
- Identity
- Immunophenotype
Drug Product
- Potency
- Transgene Functional Assay
- Viability
- Immunophenotype
- Safety
- Endotoxin
- RCL Molecular Assay
- Microbiological Control of Cell Suspension
Release, In-Process, Characterization
- Vector Copy Number
- Transduction Efficiency (Flow Cytometry)
- % T Cells (Flow Cytometry)
- Transgene ID
- Characterization
- Appearance
- Endotoxin
- Gram Stain
Safety & Stability
- Sterility, Rapid Sterility
- Mycoplasma, Rapid Mycoplasma
- RCL
Contact us to discuss how CBM’s integrated capabilities can support your program
Viral Vector Manufacturing
CBM’s viral vector capabilities efficiently and consistently delivers high yields in AAV, Lentivirus, HSV and Adenovirus vectors, accelerating the development of new therapies.
Cell Therapy Manufacturing
CBM has one of cell therapy’s most experienced teams and the largest single site facility in the industry. There is no greater centralization of expertise.
Our Experienced Team
Our team brings a wealth of experience from biopharma and advanced therapy CDMOs, ensuring that there is no safer place for your product.